Multivariate analysis of survival parameters of t(16;21)-rearranged AML
| . | pEFS . | pOS . | ||||
|---|---|---|---|---|---|---|
| . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| FUS-ERG | 2.85 | 1.93-4.21 | <.001 | 2.61 | 1.71-4.00 | <.001 |
| WBC >10 × 109/L | 1.40 | 1.15-1.70 | <.001 | 1.27 | 1.00-1.60 | .046 |
| Age >10 y | 1.14 | 0.98-1.34 | .087 | 1.38 | 1.14-1.67 | .001 |
| Time to HSCT | 0.84 | 0.63-1.12 | .23 | 0.97 | 0.70-1.33 | .834 |
| Cytogenetic SR group | 0.36 | 0.28-0.47 | <.001 | 0.25 | 0.17-0.36 | <.001 |
| RUNX1-CBFA2T3 | 0.32 | 0.12-0.87 | .025 | 0.42 | 0.14-1.33 | .140 |
| . | pEFS . | pOS . | ||||
|---|---|---|---|---|---|---|
| . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| FUS-ERG | 2.85 | 1.93-4.21 | <.001 | 2.61 | 1.71-4.00 | <.001 |
| WBC >10 × 109/L | 1.40 | 1.15-1.70 | <.001 | 1.27 | 1.00-1.60 | .046 |
| Age >10 y | 1.14 | 0.98-1.34 | .087 | 1.38 | 1.14-1.67 | .001 |
| Time to HSCT | 0.84 | 0.63-1.12 | .23 | 0.97 | 0.70-1.33 | .834 |
| Cytogenetic SR group | 0.36 | 0.28-0.47 | <.001 | 0.25 | 0.17-0.36 | <.001 |
| RUNX1-CBFA2T3 | 0.32 | 0.12-0.87 | .025 | 0.42 | 0.14-1.33 | .140 |
CI, confidence interval; pEFS, probability of event free survival; pOS, probability of overall survival.